AI assistant
ENDRA Life Sciences Inc. — Director's Dealing 2020
Oct 5, 2020
35444_dirs_2020-10-05_b61e81ce-e600-492b-9683-01b4c4fa60d1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2020-10-01
Reporting Person: Maloberti Renaud Bertrand (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-10-01 | Common Stock | S | 10000 | $0.72 | Disposed | 76580 | Direct |
Footnotes
F1: Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.72 to $0.74, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F3: Includes unvested restricted stock units.